• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antithrombotic Treatment Regimens in Patients Undergoing Percutaneous Coronary Revascularization Requiring Oral Anticoagulation: What Real-World Evidence Shows Us.

作者信息

Del Buono Marco Giuseppe, La Vecchia Giulia, Angiolillo Dominck J

机构信息

Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.

Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS,Rome, Italy.

出版信息

J Cardiovasc Pharmacol. 2024 Oct 1;84(4):391-393. doi: 10.1097/FJC.0000000000001619.

DOI:10.1097/FJC.0000000000001619
PMID:39115852
Abstract
摘要

相似文献

1
Antithrombotic Treatment Regimens in Patients Undergoing Percutaneous Coronary Revascularization Requiring Oral Anticoagulation: What Real-World Evidence Shows Us.接受经皮冠状动脉血运重建且需要口服抗凝治疗的患者的抗栓治疗方案：真实世界证据向我们展示了什么。
J Cardiovasc Pharmacol. 2024 Oct 1;84(4):391-393. doi: 10.1097/FJC.0000000000001619.
2
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.经皮冠状动脉介入治疗的口服抗凝治疗心房颤动患者的抗血栓治疗：北美视角-2018 年更新。
Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722.
3
Will We Ever Decide What Antithrombotic Regimen to Use After Stenting?我们究竟何时才能确定支架置入术后使用何种抗血栓治疗方案？
Cardiovasc Revasc Med. 2020 May;21(5):702-703. doi: 10.1016/j.carrev.2020.05.026.
4
From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.从治疗方案的选择到治疗强度的选择：接受经皮冠状动脉介入治疗的房颤患者抗栓治疗观念的转变
Cardiovasc Drugs Ther. 2020 Feb;34(1):143-144. doi: 10.1007/s10557-019-06903-y.
5
Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial.对支架置入术后病情稳定、需要长期口服抗凝治疗的冠心病患者停用与使用阿司匹林治疗的评估：AQUATIC双盲随机试验的原理与设计
Arch Cardiovasc Dis. 2025 May;118(5):296-303. doi: 10.1016/j.acvd.2025.01.006. Epub 2025 Feb 15.
6
Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations.接受经皮冠状动脉介入治疗的心房颤动患者抗血栓治疗管理算法：基于疗效考量的更新建议
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):197-198. doi: 10.1093/ehjcvp/pvaa003.
7
Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention.经皮冠状动脉介入治疗后双联与三联抗栓治疗的真实临床经验。
Catheter Cardiovasc Interv. 2018 Dec 1;92(7):1239-1246. doi: 10.1002/ccd.27678. Epub 2018 Jul 18.
8
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?在接受经皮冠状动脉介入治疗的心房颤动患者中停用阿司匹林：这是一次配备薄弱降落伞的跳跃吗？
Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):55-56. doi: 10.1093/ehjcvp/pvy039.
9
Focus on pharma in acute coronary syndrome.关注急性冠状动脉综合征中的药物治疗。
Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):1-2. doi: 10.1093/ehjcvp/pvz074.
10
Safety and Efficacy of Oral Anticoagulants Therapies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis.口服抗凝药物治疗在经皮冠状动脉介入治疗的心房颤动患者中的安全性和疗效：一项网状荟萃分析。
J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):399-408. doi: 10.1177/1074248420930136. Epub 2020 Jun 3.